CCND1 Amplification Mediated Gefitinib Resistance in NSCLC

Overview of attention for article published in Frontiers in Pharmacology, June 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,015 followers.

New article: LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC https://t.co/TNoW0x05Xr #lungcancer #oncology https://t.co/vsq9F5pn99

11 Jul 2022

Reply Repost Favourite

RT @FrontPharmacol: New Research: LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC ht…

24 Jun 2022

Reply Repost Favourite

New Research: LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC https://t.co/6vMYKSbQip #pharmacology

23 Jun 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.